Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 09, 2015 3:02 PM ET


Company Overview of Q Therapeutics, Inc.

Company Overview

Q Therapeutics, Inc., a clinical-stage company, engages in developing human cell-based therapies intended to treat neurodegenerative diseases of the brain and spinal cord. Its product candidate includes Q-Cells that are healthy human glial progenitor cells intended to restore or preserve normal activity of neurons by providing support functions that occur in healthy central nervous system (CNS) tissues. The company develops Q-Cells for application in a range of CNS diseases, including multiple sclerosis, transverse myelitis, cerebral palsy, and stroke, as well as other neurodegenerative diseases and injuries, such as amyotrophic lateral sclerosis, Huntington’s disease, spinal cord injury, st...

615 Arapeen Drive

Suite 102

Salt Lake City, UT 84108

United States

5 Employees





Key Executives for Q Therapeutics, Inc.

Chairman, Chief Executive Officer and President
Age: 57
Vice President of Research & Development
Age: 66
Regulatory Consultant
Compensation as of Fiscal Year 2015.

Q Therapeutics, Inc. Key Developments

Q Therapeutics, Inc. Announces Management Changes

Effective September 8, 2015, Deborah Eppstein resigned as President and Chief Executive Officer of Q Therapeutics, Inc. Ms. Eppstein has entered into a consulting agreement to assist the company with matters regarding the strategy, filing and prosecuting Companycs intellectual property portfolio, and other information related to developing cell therapy products for treatment of neurodegenerative diseases and injuries for an initial term of one year. Effective September 9, 2015, Steven J. Borst, was appointed to serve as President and Chief Executive Officer of the company. Mr. Borst, age 58, has served as the company's Chief Financial Officer and Principal Accounting Officer since October 13, 2011. On September 9, 2015, the Board of Directors of the company appointed Steven J. Borst as a member of the board and as Chairman of the Board.

Q Therapeutics, Inc. Announces Clearance of its Investigational New Drug Application for Phase 1/2A Clinical Trials with Q-Cells in Patients with ALS

Q Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) for the initiation of Phase 1/2a clinical trials of its Q-Cells product in patients with amyotrophic lateral sclerosis (ALS). Also known as Lou Gehrig's disease, ALS is a devastating condition caused by degeneration of motor neurons, the nerve cells in the brain and spinal cord that control muscle movement. ALS affects more than 30,000 people in the U.S. at any given time and nearly half a million people worldwide. There is no effective therapy for ALS and it is 80% fatal within five years of diagnosis. Q-Cells, the Company's first patented cellular therapeutic product candidate, are glial-restricted progenitor cells (GRPs) - early descendants of neural stem cells that produce only glia - which make up 50% of cells in the brain. Glia are essential for supporting, maintaining and even restoring neuron health. The FDA's clearance of Q Therapeutics' Investigational New Drug (IND) application for Phase 1/2a clinical trials with Q-Cells in ALS patients confirms that the preclinical data are sufficient to allow initiation of the first-ever human trials evaluating the use of GRPs to treat ALS patients. Published pre-clinical data in animal models of ALS and other central nervous system (CNS) Stained Q-Cell in culture, during differentiation, with yellow showing diseases have demonstrated that delivery of healthy glial cells into the early progenitor characteristics, and red highlighting a protein found brain and spinal cord has the potential to modify the course of currently later in astrocytes, the cell type thought to be beneficial for ALS incurable CNS diseases and injuries.

Q Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Q Therapeutics, Inc. filed its 10-K on Mar 31, 2015 for the period ending Dec 31, 2014. In this report its auditor, Tanner + Co., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Similar Private Companies By Industry

Company Name Region
Gemmus Pharma Inc. United States
STC Biologics, Inc. United States
BioMachines Inc. United States
miRagen Therapeutics, Inc. United States
MSC Regenos United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Q Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at